| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
Departments of 1 Medicine, 2 Pathology, and 3 Surgery, University of Chicago; 4 Department of Medicine, University of Illinois at Chicago, Chicago, Illinois; 5 Department of Medicine, Mayo Clinic, Rochester, Minnesota; and 6 Department of Medicine, University of California, San Diego, California
Requests for reprints: Marc Bissonnette, Department of Medicine, University of Chicago Hospitals and Clinics, MC 4076, 5841 South Maryland Avenue, Chicago, IL 60637. Phone: 773-702-8597; Fax: 773-702-2182; E-mail: mbissonn{at}medicine.bsd.uchicago.edu.
Aberrant crypt foci (ACF) are collections of abnormal colonic crypts with heterogeneous molecular and pathologic characteristics. Large and dysplastic ACF are putative precursors of colon cancer with neoplastic risk related to increased proliferation. In this study, we examined the role of epidermal growth factor receptor (EGFR) signaling in regulating ACF proliferation. Using magnification chromoendoscopy, we collected large ACF with endoscopic features of dysplasia and separately biopsied adjacent mucosa. Transcript levels were measured by real-time PCR, proteins were assessed by Western blotting, and levels were expressed as fold changes of adjacent mucosa. K-ras and B-Raf mutations were assessed by PCR and Ras activation by the ratio Ras-GTP / (Ras-GTP + Ras-GDP). At the RNA level, 38% of ACF were hyperproliferative, with proliferating cell nuclear antigen (PCNA) mRNA
2-fold of adjacent mucosa. Hyperproliferative ACF had significantly increased mRNA levels of EGFR (6.0 ± 1.7fold), transforming growth factor-
(14.4 ± 5.0fold), heparin-binding EGF-like growth factor (4.5 ± 1.4fold), cyclin D1 (4.6 ± 0.7fold), and cyclooxygenase-2 (COX-2; 9.3 ± 4.2fold; P < 0.05). At the protein level, 46% of ACF were hyperproliferative (PCNA, 3.2 ± 1.2fold). In hyperproliferative ACF, 44% possessed significant increases in four EGFR signaling components: EGFR (9.5 ± 1.3fold), phosphoactive ErbB2 (2.6 ± 0.4fold), phosphoactive extracellular signal-regulated kinase (3.7 ± 1.1fold), and cyclin D1 (3.4 ± 0.8fold; P < 0.05). Ras was activated in 46% of ACF (3.2 ± 0.4fold; P < 0.05), but K-ras mutations were present in only 7% of ACF. In contrast to COX-2 mRNA, the protein was not increased in hyperproliferative ACF. In summary, we have shown that ACF with up-regulated PCNA possess increased EGFR signaling components that likely contribute to the enhanced proliferative state of dysplastic-appearing ACF. (Cancer Res 2006; 66(11): 5656-64)
This article has been cited by other articles:
![]() |
F. C. Denison, S. Battersby, A. E. King, M. Szuber, and H. N. Jabbour Prokineticin-1: A Novel Mediator of the Inflammatory Response in Third-Trimester Human Placenta Endocrinology, July 1, 2008; 149(7): 3470 - 3477. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lance and S. R. Hamilton Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention Cancer Prevention Research, June 1, 2008; 1(1): 4 - 8. [Full Text] [PDF] |
||||
![]() |
U. Dougherty, A. Sehdev, S. Cerda, R. Mustafi, N. Little, W. Yuan, S. Jagadeeswaran, A. Chumsangsri, J. Delgado, M. Tretiakova, et al. Epidermal Growth Factor Receptor Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane Model Clin. Cancer Res., April 15, 2008; 14(8): 2253 - 2262. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Schmelz, H. Xu, R. Sengupta, J. Du, S. Banerjee, F. H. Sarkar, A. K. Rishi, and A. P.N. Majumdar Regression of Early and Intermediate Stages of Colon Cancer by Targeting Multiple Members of the EGFR Family with EGFR-Related Protein Cancer Res., June 1, 2007; 67(11): 5389 - 5396. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fichera, N. Little, S. Jagadeeswaran, U. Dougherty, A. Sehdev, R. Mustafi, S. Cerda, W. Yuan, S. Khare, M. Tretiakova, et al. Epidermal Growth Factor Receptor Signaling Is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic Carcinogenesis Cancer Res., January 15, 2007; 67(2): 827 - 835. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |